Use of Capsaicin/TRPV1 agonists for prevention of diabetic foot ulcers

Reference number 10741

Sectors: Healthcare, Pharmaceuticals

Industries: Diabetes, Pharmaceuticals, Therapeutics

Topical use of Capsaicin or TRPV 1 agonists for the prevention of diabetic ulcers in a patient suffering from diabetic peripheral neuropathy (DPN).

Proposed use

  • Repeated topical administration of a capsaicinoid or TRPV1 agonist to one or more areas of the skin, for the prevention of diabetic foot ulcers.
  • Use of a capsaicinoid or TRPV1 agonist to induce or enhance the regeneration of small sensory nerve fibres in patients with both painful and non-painful DPN.

Problem addressed

Diabetic Peripheral Neuropathy (DPN) refers to peripheral neuropathy (whether painful or non-painful) induced by diabetes mellitus. The underlying mechanisms are diverse, yet progressive loss of small sensory nerve fibres has been found to occur in diabetic patients, playing a major role in the development of diabetic foot ulcers. Among the diabetic population, there exists a significant lifetime risk of 25% for developing diabetic foot ulceration. Tragically, a majority of these cases will require amputation within four years of initial diagnosis. Such complications are directly linked to a higher mortality risk. Currently, there is no approved treatment available to prevent nerve fibre loss or promote nerve regeneration in DPN. However, the topical administration of a patch containing Capsaicin, or an equivalent TRPV1 agonist to the skin of a patient, holds promising potential to address this issue by inducing nerve regeneration.

Technology overview

The key features of this technology include:

  • The topical administration of a capsaicinoid or TRPV1 agonist to one or more areas of the skin, for the prevention of diabetic foot ulcers.
  • A kit, comprising: a cutaneous patch; and a leaflet, where the cutaneous patch contains capsaicin or a capsaicinoid or a TRPV1 agonist, and the leaflet provides instructions for a method of preventing diabetic ulcers.


  • Prevents development of foot ulcers in diabetic patients
  • Promotes nerve regeneration in DPN.
  • Reduces the burden of Diabetic Foot Syndrome on patients, carers and financial resources.

Intellectual property information

An International PCT application (WO2022/053820) has been filed.


Professor Praveen Anand

Professor of Clinical Neurology
Faculty of Medicine, Department of Brain Sciences

Visit personal site


Dr Amritha Nair

Industry Partnerships and Commercialisation Senior Executive, Faculty of Medicine

Dr Amritha Nair is an Industry Partnerships and Commercialisation Senior Executive in the Faculty of Medicine at Imperial College London. Amritha works across the entire innovation lifecycle from assessment, protection, and management of Intellectual property; marketing of technologies primed for commercialisation and supporting commercialisation via licensing or spinouts. Amritha also supports researchers in their bids for access to translational funding. Amritha manages an extensive IP portfolio, mainly focussed on therapeutics and diagnostics. Prior roles include innovation consulting for small and medium enterprises and handling the drug development and start-up activities for a private equity backed life science development group in Houston, USA. Amritha has a PhD in Molecular and Human Genetics from Baylor College of Medicine, Houston, USA and a MSc in Human Genetics from Sri Ramachandra University, Chennai, India.

Contact Amritha

[email protected]

Related technologies

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.